

INVERESK RESEARCH GROUP INC
Form 425
July 29, 2004

Filed by Charles River Laboratories International, Inc.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12 under the
Securities Exchange Act of 1934

Subject Company: Inveresk Research Group, Inc
Commission File No.: 000-49765

The following press release was issued by Charles River Laboratories International, Inc. on July 28, 2004.

NEWS RELEASE

CHARLES RIVER LABORATORIES ANNOUNCES RECORD SECOND-QUARTER 2004 RESULTS AND INCREASES GUIDANCE FOR 2004

- Sales Increase 17% and Operating Income Increases 26% -

- Operating Margin Reaches a Record 24.5% -

- Earnings Per Share Rise 24% to \$0.52 -

WILMINGTON, MA, July 28, 2004, (Businesswire) □ Charles River Laboratories International, Inc. (NYSE:CRL) today reported second-quarter 2004 net sales of \$180.2 million, a 16.7% increase over the \$154.4 million reported in the second quarter of 2003. Net income for the second quarter of 2004 increased 27.9% to \$26.3 million, or \$0.52 per diluted share, from \$20.6 million, or \$0.42 per diluted share, in the second quarter of 2003. Last year's second-quarter results included a \$0.9 million charge, or \$0.01 per diluted share, resulting from a cost reduction program undertaken in the Development and Safety Testing segment.

Operating income for the second quarter of 2004 rose 26.3% to \$44.2 million from \$35.0 million in the second quarter of last year. The Company's operating margin increased to 24.5% compared to 22.7% in the second quarter of last year. The operating margin increase resulted from higher sales and improved operating efficiency in both the Research Models and Services segment and the Development and Safety Testing segment.

James C. Foster, Chairman, President and Chief Executive Officer said, "We are very pleased with our second-quarter results. The value of our portfolio of essential products and services and our focused sales efforts are evident in our performance. Both business segments delivered strong results, benefiting from increased spending on drug discovery and development by pharmaceutical and biotechnology companies and by academic research institutions. By maintaining a consistent focus on expense management, we have leveraged significantly higher sales to generate an operating margin of 24.5%, the highest margin ever achieved by the Company."

Mr. Foster continued, "The investment we made over the last eighteen months to streamline our Development Services business has positioned us extremely well to compete effectively in the robust market for outsourced drug development services. We are optimistic about our future performance both because of our positioning and our belief that the current market climate will continue through 2004 and beyond."

Business Segments Results

Second-quarter 2004 net sales for the Research Models and Services (RMS) segment of the business were \$113.3 million compared to \$102.5 million last year, an increase of 10.6%. The double-digit growth reflected higher prices, increased customer demand, and favorable foreign currency translation. Increased capacity utilization resulted in a gross margin of 43.6%, compared to 42.0% in the second quarter of last year. Higher sales and increased operating efficiencies resulted in a 19.5% increase in operating income, to \$38.0 million in the second quarter with an operating margin of 33.5%, compared to last year's \$31.8 million and 31.0%.

Net sales for the Development and Safety Testing (DST) segment rose 28.9% in the second quarter, to \$66.9 million from \$51.9 million in the same period last year. The Company's efforts to integrate and harmonize its Development Services business and to focus its sales efforts positioned it to benefit from stronger customer demand for outsourced services, particularly in general and specialty toxicology. The segment's gross margin increased to 37.7% from 31.9% in the second quarter of 2003. Operating income doubled to \$14.4 million from \$7.3 million in the second quarter of last year. The second-quarter operating margin increased to 21.6% from 14.1% last year, reflecting greater operating efficiencies as a result of higher sales, and the benefit of efforts to streamline the Development Services business.

Year-to-Date Results

Net sales for the first six months of 2004 were \$352.8 million, a 15.1% increase over the \$306.5 million reported in the same period last year. As a result of higher net sales and increased capacity utilization, the gross margin rose to 40.7% from 38.4% in the first half of 2003. Operating income increased 21.6% to \$83.7 million from \$68.9 million last year, and the operating margin increased to 23.7% from 22.5%, due to improved operating performance from the DST segment.

Diluted earnings per share for the first half of 2004 increased to \$0.88 from \$0.82 in the same period last year, or 7.3%. Non-GAAP earnings per diluted share rose 17.9% in the first six months of 2004, to \$0.99 from \$0.84 in the first half of 2003. Non-GAAP earnings per share for the first six months of 2004 excluded a net charge of \$5.8 million, or approximately \$0.11 per diluted share, related to the write-off of a deferred tax asset and release of a related tax valuation allowance. Non-GAAP earnings per share for the first six months of 2003 excluded a net charge of \$1.7 million, or approximately \$0.02 per diluted share, as a result of an asset impairment charge of \$3.7 million related to the scale-back of a biopharmaceutical production facility, a French litigation settlement in the Company's favor of \$2.9 million, and a charge of \$0.9 million for expenses associated with cost reduction initiatives. Charles River believes that the foregoing comparison of non-GAAP earnings is useful to investors in assessing the performance of the business on an ongoing basis, since the specified charges are unusual in nature.

Merger with Inveresk Research Group

On July 1, 2004, Charles River Laboratories and Inveresk Research Group announced that their respective Boards of Directors had approved a definitive merger agreement to create a leading global provider of essential preclinical and clinical drug development products and services to the pharmaceutical and biotechnology industry. On July 21, 2004, the companies announced that the Federal Trade Commission had granted early termination of the waiting period required by Hart-Scott-Rodino in connection with the merger. Subject to additional regulatory and shareholder approvals, the Company expects the merger to close in the fourth quarter of 2004.

2004 Outlook

The following forward-looking guidance is based on current foreign exchange rates and is exclusive of the Inveresk merger or any acquisitions which may occur. Since it is uncertain when in the fourth quarter the Inveresk merger would occur, it is impracticable to provide an estimate of the combined company's operating results or any related GAAP reconciliations. Closing of the merger with Inveresk could cause actual results to be materially different from the forward-looking guidance.

For 2004, the Company anticipates that net sales will increase between 12% and 16%, higher than previous guidance of 9% to 13% due to the more robust business environment. As a result of stronger sales growth, the Company now expects 2004 earnings per diluted share to be in a range of \$1.79 to \$1.85. Excluding the one-time net charge associated with the reorganization of the European operations, non-GAAP earnings per diluted share are expected to be \$1.90 to \$1.96, compared to the Company's earlier guidance of \$1.83 to \$1.89.

For the third quarter of 2004, the Company expects net sales to increase between 14% and 16% due to higher sales in both the RMS and DST business segments. Based on higher net sales and operating efficiencies, earnings per diluted share are expected to be in a range of \$0.48 to \$0.50.

Webcast

Charles River Laboratories has scheduled a live webcast on Thursday, July 29, at 8:30 a.m. EDT to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. The webcast will be available until 5:00 p.m. EDT on August 5, 2004.

Charles River Laboratories, based in Wilmington, Massachusetts, is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. The Company is a global leader in providing the animal research models required in research and development for new drugs, devices and therapies. The Company also offers a broad and growing portfolio of products and services that enable customers to reduce cost, increase speed, and enhance productivity and effectiveness in drug discovery and development. Charles River's customer base

spans over 50 countries, and includes all of the major pharmaceutical companies, biotechnology companies, and many leading hospitals and academic institutions.

Caution Concerning Forward-Looking Statements. This document includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on management's current expectations, and involve a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the forward-looking statements, and the Company expressly does not undertake any duty to update forward-looking statements, which speak only as of the date of this document. Those risks and uncertainties include, but are not limited to: the proposed merger with Inveresk; a decrease in pre-clinical research and development spending or a decrease in the level of outsourced services; acquisition integration risks; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company's Annual Report on Form 10-K as filed on March 10, 2004, with the Securities and Exchange Commission.

Additional Information

This press release may be deemed to be solicitation material in respect of the proposed merger of Charles River and Inveresk. In connection with the proposed transaction, a registration statement on Form S-4 will be filed with the SEC. SHAREHOLDERS OF CHARLES RIVER AND SHAREHOLDERS OF INVERESK ARE URGED TO READ THE REGISTRATION STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE JOINT PROXY STATEMENT/PROSPECTUS THAT WILL BE PART OF THE REGISTRATION STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. The final joint proxy statement/prospectus will be mailed to shareholders of Charles River and shareholders of Inveresk. Investors and security holders will be able to obtain the documents free of charge at the SEC's website, www.sec.gov, from Charles River Laboratories, 251 Ballardvale Street, Wilmington, MA 01887, Attention: General Counsel, or from Inveresk Research Group, 11000 Weston Parkway, Cary, North Carolina 27513, Attention: Secretary. In addition, shareholders may access copies of the documentation filed with the SEC by Charles River on Charles River's website at www.criver.com and shareholders may access copies of the documents filed with the SEC by Inveresk on Inveresk's website at www.inveresk.com.

4

Charles River, Inveresk and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from their respective shareholders in respect of the proposed transactions. Information regarding Charles River's directors and executive officers is available in Charles River's proxy statement for its 2004 annual meeting of shareholders, which was filed with the SEC on April 9, 2004, and information regarding Inveresk's directors and executive officers is available in Inveresk's proxy statement for its 2004 annual meeting of shareholders, which was filed with the SEC on March 31, 2004. Additional information regarding the interests of such potential participants will be included in the joint proxy statement/prospectus and the other relevant documents filed with the SEC when they become available.

#

Investor Contact:
Susan E. Hardy
Director, Investor Relations
978.658.6000 Ext. 1616

5

**CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(dollars in thousands, except for per share data)**

| <u>Three Months Ended</u> | | <u>Six Months Ended</u> | |
|---------------------------|--------------------------|--------------------------|--------------------------|
| June 26, 2004 | June 28, 2003 | June 26, 2004 | June 28, 2003 |

Edgar Filing: INVERESK RESEARCH GROUP INC - Form 425

| | | | | |
|--|------------|------------|------------|------------|
| Total net sales | \$ 180,193 | \$ 154,364 | \$ 352,830 | \$ 306,489 |
| Cost of products sold and services provided | 105,572 | 94,779 | 209,381 | 188,922 |
| | <hr/> | <hr/> | <hr/> | <hr/> |
| Gross margin | 74,621 | 59,585 | 143,449 | 117,567 |
| Selling, general and administrative | 29,220 | 23,349 | 57,340 | 45,488 |
| Other operating expenses, net | - | - | - | 747 |
| Amortization of intangibles | 1,198 | 1,230 | 2,389 | 2,478 |
| | <hr/> | <hr/> | <hr/> | <hr/> |
| Operating income | 44,203 | 35,006 | 83,720 | 68,854 |
| Interest income (expense) | (1,310) | (1,713) | (2,725) | (3,299) |
| Other, net | (73) | 434 | 127 | 416 |
| | <hr/> | <hr/> | <hr/> | <hr/> |
| Income before income taxes and minority interests | 42,820 | 33,727 | 81,122 | 65,971 |
| Provision for income taxes | 16,058 | 12,985 | 36,210 | 25,399 |
| | <hr/> | <hr/> | <hr/> | <hr/> |
| Income before minority interests | 26,762 | 20,742 | 44,912 | 40,572 |
| Minority interests | (462) | (181) | (1,018) | (657) |
| | <hr/> | <hr/> | <hr/> | <hr/> |
| Net income | \$ 26,300 | \$ 20,561 | \$ 43,894 | \$ 39,915 |
| | <hr/> | <hr/> | <hr/> | <hr/> |
| Earnings per common share | | | | |
| Basic | \$ 0.57 | \$ 0.45 | \$ 0.96 | \$ 0.88 |
| Diluted | \$ 0.52 | \$ 0.42 | \$ 0.88 | \$ 0.82 |
| Weighted average number of common shares outstanding | | | | |
| Basic | 46,046,675 | 45,319,310 | 45,950,897 | 45,248,913 |
| Diluted | 52,586,287 | 51,239,609 | 52,342,036 | 51,220,986 |

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(dollars in thousands)

| | June 26, 2004 | December 27, 2003 |
|---------------------------|--------------------------|----------------------------------|
| Assets | | |
| Current assets | | |
| Cash and cash equivalents | \$ 224,153 | \$ 182,331 |
| Marketable securities | 10,506 | 13,156 |
| Trade receivables, net | 124,978 | 111,514 |
| Inventories | 54,676 | 52,370 |
| Other current assets | 10,297 | 11,517 |
| | <hr/> | <hr/> |

Edgar Filing: INVERESK RESEARCH GROUP INC - Form 425

| | | |
|------------------------------------|------------|------------|
| Total current assets | 424,610 | 370,888 |
| Property, plant and equipment, net | 205,885 | 203,458 |
| Goodwill, net | 113,691 | 105,308 |
| Other intangibles, net | 32,158 | 30,415 |
| Deferred tax asset | 53,126 | 61,603 |
| Other assets | 32,914 | 27,882 |
| | <hr/> | <hr/> |
| Total assets | \$ 862,384 | \$ 799,554 |
| | <hr/> | <hr/> |

Liabilities and Shareholders' Equity

| | | |
|--|------------|------------|
| Current liabilities | | |
| Accounts payable | \$ 16,451 | \$ 19,433 |
| Accrued compensation | 29,811 | 27,251 |
| Deferred income | 33,603 | 30,846 |
| Other current liabilities | 42,496 | 36,821 |
| | <hr/> | <hr/> |
| Total current liabilities | 122,361 | 114,351 |
| Long-term debt | 185,500 | 185,600 |
| Other long-term liabilities | 25,977 | 24,804 |
| | <hr/> | <hr/> |
| Total liabilities | 333,838 | 324,755 |
| | <hr/> | <hr/> |
| Minority interests | 9,484 | 10,176 |
| Total shareholders' equity | 519,062 | 464,623 |
| | <hr/> | <hr/> |
| Total liabilities and shareholders' equity | \$ 862,384 | \$ 799,554 |
| | <hr/> | <hr/> |

**CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)**

| | <u>Three Months Ended</u> | | <u>Six Months Ended</u> | |
|--------------------------------------|---------------------------|--------------------------|--------------------------|--------------------------|
| | June 26, 2004 | June 28, 2003 | June 26, 2004 | June 28, 2003 |
| Research Models and Services | | | | |
| Net sales | \$ 113,334 | \$ 102,500 | \$ 226,800 | \$ 205,623 |
| Gross margin | 49,401 | 43,054 | 98,289 | 87,939 |
| Gross margin as a % of net sales | 43.6% | 42.0% | 43.3% | 42.8% |
| Operating income | 38,007 | 31,798 | 74,486 | 69,036 |
| Operating income as a % of net sales | 33.5% | 31.0% | 32.8% | 33.6% |
| Depreciation and amortization | 4,144 | 3,940 | 8,286 | 7,530 |
| Capital expenditures | 4,319 | 2,363 | 7,490 | 4,527 |

Development and Safety Testing

| | | | | |
|--------------------------------------|-----------|-----------|------------|------------|
| Net sales | \$ 66,859 | \$ 51,864 | \$ 126,030 | \$ 100,866 |
| Gross margin | 25,220 | 16,531 | 45,160 | 29,628 |
| Gross margin as a % of net sales | 37.7% | 31.9% | 35.8% | 29.4% |
| Operating income | 14,431 | 7,320 | 24,277 | 8,251 |
| Operating income as a % of net sales | 21.6% | 14.1% | 19.3% | 8.2% |
| Depreciation and amortization | 3,552 | 3,191 | 7,247 | 6,526 |
| Capital expenditures | 3,023 | 6,855 | 4,377 | 9,927 |

Unallocated Corporate Overhead \$ (8,235) \$ (4,112) \$ (15,043) \$ (8,433)

Total

| | | | | |
|--------------------------------------|------------|------------|------------|------------|
| Net sales | \$ 180,193 | \$ 154,364 | \$ 352,830 | \$ 306,489 |
| Gross margin | 74,621 | 59,585 | 143,449 | 117,567 |
| Gross margin as a % of net sales | 41.4% | 38.6% | 40.7% | 38.4% |
| Operating income | 44,203 | 35,006 | 83,720 | 68,854 |
| Operating income as a % of net sales | 24.5% | 22.7% | 23.7% | 22.5% |
| Depreciation and amortization | 7,696 | 7,131 | 15,533 | 14,056 |
| Capital expenditures | 7,342 | 9,218 | 11,867 | 14,454 |

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS
(dollars in thousands, except for per share data)

| | <u>Three Months Ended</u> | | <u>Six Months Ended</u> | |
|--|---------------------------|--------------------------|--------------------------|--------------------------|
| | <u>June 26, 2004</u> | <u>June 28, 2003</u> | <u>June 26, 2004</u> | <u>June 28, 2003</u> |
| Net income | \$ 26,300 | \$ 20,561 | \$ 43,894 | \$ 39,915 |
| Add back: | | | | |
| Deferred tax asset write-off | - | - | 7,900 | - |
| Valuation allowance release | - | - | (2,111) | - |
| Impairment charge | - | - | - | 3,655 |
| Litigation settlement | - | - | - | (2,908) |
| Severance charges | - | 871 | - | 871 |
| Tax effect of impairment charge, litigation settlement and severance charges | - | (335) | - | (623) |
| Net income, excluding specified charges (Non-GAAP) | <u>\$ 26,300</u> | <u>\$ 21,097</u> | <u>\$ 49,683</u> | <u>\$ 40,910</u> |

Calculation of earnings per common share

Edgar Filing: INVERESK RESEARCH GROUP INC - Form 425

excluding specified charges (Non-GAAP):

Net income for purposes of calculating earnings per share

| | | | | |
|--|-----------|-----------|-----------|-----------|
| excluding specified charges (Non-GAAP) | \$ 26,300 | \$ 21,097 | \$ 49,683 | \$ 40,910 |
|--|-----------|-----------|-----------|-----------|

After-tax equivalent interest expense on 3.5% senior

| | | | | |
|------------------------|-----|-----|-------|-------|
| convertible debentures | 995 | 995 | 1,991 | 1,991 |
|------------------------|-----|-----|-------|-------|

Income for purposes of calculating fully diluted earnings

| | | | | |
|---|-----------|-----------|-----------|-----------|
| per share, excluding specified charges (Non-GAAP) | \$ 27,295 | \$ 22,092 | \$ 51,674 | \$ 42,901 |
|---|-----------|-----------|-----------|-----------|

| | | | | |
|---|------------|------------|------------|------------|
| Weighted average shares outstanding - Basic | 46,046,675 | 45,319,310 | 45,950,897 | 45,248,913 |
|---|------------|------------|------------|------------|

Effect of dilutive securities:

| | | | | |
|------------------------------------|-----------|-----------|-----------|-----------|
| 3.5% senior convertible debentures | 4,759,455 | 4,759,455 | 4,759,455 | 4,759,455 |
|------------------------------------|-----------|-----------|-----------|-----------|

| | | | | |
|--|-----------|---------|-----------|---------|
| Stock options and contingently issued restricted stock | 1,440,297 | 747,095 | 1,294,509 | 775,189 |
|--|-----------|---------|-----------|---------|

| | | | | |
|----------|---------|---------|---------|---------|
| Warrants | 339,860 | 413,749 | 337,175 | 437,429 |
|----------|---------|---------|---------|---------|

| | | | | |
|---|------------|------------|------------|------------|
| Weighted average shares outstanding - Diluted | 52,586,287 | 51,239,609 | 52,342,036 | 51,220,986 |
|---|------------|------------|------------|------------|

| | | | | |
|--------------------------|---------|---------|---------|---------|
| Basic earnings per share | \$ 0.57 | \$ 0.45 | \$ 0.96 | \$ 0.88 |
|--------------------------|---------|---------|---------|---------|

| | | | | |
|----------------------------|---------|---------|---------|---------|
| Diluted earnings per share | \$ 0.52 | \$ 0.42 | \$ 0.88 | \$ 0.82 |
|----------------------------|---------|---------|---------|---------|

Basic earnings per share, excluding specified charges

| | | | | |
|------------|---------|---------|---------|---------|
| (Non-GAAP) | \$ 0.57 | \$ 0.47 | \$ 1.08 | \$ 0.90 |
|------------|---------|---------|---------|---------|

Diluted earnings per share, excluding specified charges

| | | | | |
|------------|---------|---------|---------|---------|
| (Non-GAAP) | \$ 0.52 | \$ 0.43 | \$ 0.99 | \$ 0.84 |
|------------|---------|---------|---------|---------|

Charles River management believes that non-GAAP financial results provide useful information to investors in being able to assess the Company's ongoing operations without the effect of one-time charges. Such information provide investors with the ability to assess the Company's operating performance. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations.